A drug interaction study of a novel P38 MAP kinase inhibitor with methotrexate in rheumatoid arthritis patients.

Trial Profile

A drug interaction study of a novel P38 MAP kinase inhibitor with methotrexate in rheumatoid arthritis patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2010

At a glance

  • Drugs Pamapimod (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 25 Jan 2010 Results were published in the Journal of Clinical Pharmacology.
    • 26 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top